Effects of 5-bromotetrandrine and daunorubicin on apoptosis and expression of survivin in K562/A02 cells.
- Author:
Xiao-Hui CAI
1
;
Bao-An CHEN
;
Jian CHENG
;
Jun WANG
;
Jia-Hua DING
;
Wen BAO
;
Yue-Jiao ZHONG
;
Feng GAO
;
Wen-Lin XU
;
Hui-Ling SHEN
;
Hu-Lai WEI
;
Jing CHEN
Author Information
1. Department of Hematology, Medical School of Southeast University, Nanjing 210009, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
drug effects;
genetics;
Benzylisoquinolines;
pharmacology;
Daunorubicin;
pharmacology;
Drug Resistance, Multiple;
genetics;
Drug Resistance, Neoplasm;
genetics;
Gene Expression Regulation, Leukemic;
Humans;
Inhibitor of Apoptosis Proteins;
genetics;
K562 Cells
- From:
Journal of Experimental Hematology
2011;19(1):24-27
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the potential benefit of combination therapy with 5-bromotetrandrine (5-BrTet) and daunorubicin (DNR) on chronic leukemia. The apoptosis of K562/A02 cells treated by DNA, BrTet and BrTet combined with DNR for 48 hours was detected by flow cytometry; the expressions levels of survivin mRNA and protein K562/A02 cells treated by DNR, BrTet and BrTet combined with DNR and in untreated K562 cells for 48 hours were measured by RT-PCR and Western blot respectively. The results showed that the combination of BrTet with DNR increased apoptotic rate of K562/A02, down-regulated the expression levels of survivin mRNA and protein in K562/A02 cells as compared with blank control and cells treated by BrTet or DNR alone, the survivin expression in K562/A02 cells was higher than that in K562 cells. It is concluded that the combination of BrTet with DNR can effectively reverse the multidrug resistance of K562/A02 cells, promote the apoptosis of K562/A02 cells, the mechanism of which may be related with down-regulation of survivin expression. Survivin may be a target for the treatment of MDR in hematopoietic malignancies.
